Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Scribed by Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clotet; Nathan Clumeck; Ya-Pei Liu; Lijie Zhong; Nicolas Margot; Andrew K Cheng; Steven L Chuck

• Book ID: 117791917
• Publisher: The Lancet
• Year: 2012
• Tongue: English
• Weight: 209 KB
• Volume: 12
• Category: Article
• ISSN: 1473-3099
• DOI: 10.1016/s1473-3099(11)70249-3